Skip to main content
Erschienen in: Hepatology International 5/2016

31.05.2016 | Editorial

HBsAg loss in chronic hepatitis B: pointers to the benefits of curative therapy

verfasst von: Geoffrey Dusheiko, Bo Wang, Ivana Carey

Erschienen in: Hepatology International | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Excerpt

Hepatitis B surface antigen (HBsAg) clearance is a relatively rare outcome during the complex natural history of chronic hepatitis B [1]. The estimated annual incidence of clearance of HBsAg is 1–2 % in Asian and in Western populations [2]. Annual rates of HBsAg loss in HBeAg-negative patients may be higher in those with lower levels of hepatitis B replication, minimal hepatitis and normal serum aminotransferases [3]. Hepatitis B genotype and mode of acquisition may influence the rate of HBsAg loss. Spontaneous seroclearance of HBsAg is thought to be beneficial, and to confer an improved outlook; thus HBsAg concentrations and loss may be a useful biomarker of prognosis in patients with chronic hepatitis B [4]. HBsAg loss may also occur, although relatively rarely, after interferon-alpha treatment or nucleoside analogue anti-viral therapy [57]. Likewise, the prognosis is improved, and thus HBsAg loss, rather than merely HBV DNA suppression, has become an important goal of potential curative therapies for hepatitis B. …
Literatur
1.
Zurück zum Zitat Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582–592 Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582–592
2.
Zurück zum Zitat Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010;15:133–143 Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010;15:133–143
3.
Zurück zum Zitat Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, You SL, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010;139:474–482 Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, You SL, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010;139:474–482
4.
Zurück zum Zitat Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, Siu CW, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004;39:1694–1701 Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, Siu CW, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004;39:1694–1701
5.
Zurück zum Zitat Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Schall RA, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci 2015;60:1457–1464 Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Schall RA, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci 2015;60:1457–1464
6.
Zurück zum Zitat Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, Lee HC, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut 2014;63:1325–1332 Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, Lee HC, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut 2014;63:1325–1332
7.
Zurück zum Zitat Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 2006;119:71.e79–16 Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 2006;119:71.e79–16
8.
Zurück zum Zitat Idilman R, Cinar K, Seven G, Bozkus Y, Elhan A, Bozdayi M, Yurdaydin C, et al. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients. J Viral Hepat 2012;19:220–226 Idilman R, Cinar K, Seven G, Bozkus Y, Elhan A, Bozdayi M, Yurdaydin C, et al. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients. J Viral Hepat 2012;19:220–226
9.
Zurück zum Zitat Seto WK, Tanaka Y, Wong DK, Shinkai N, Cheung KS, Liu KS, Fung J, et al. Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance. Liver Int 2016;36(5):642–650 Seto WK, Tanaka Y, Wong DK, Shinkai N, Cheung KS, Liu KS, Fung J, et al. Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance. Liver Int 2016;36(5):642–650
10.
Zurück zum Zitat Saitta C, Tripodi G, Barbera A, Bertuccio A, Smedile A, Ciancio A, Raffa G, et al. Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma. Liver Int 2015;35:2311–2317 Saitta C, Tripodi G, Barbera A, Bertuccio A, Smedile A, Ciancio A, Raffa G, et al. Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma. Liver Int 2015;35:2311–2317
11.
Zurück zum Zitat Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, Gill H, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 2014;32:3736–3743 Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, Gill H, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 2014;32:3736–3743
12.
Zurück zum Zitat Lim TH, Gane E, Moyes C, Borman B, Cunningham C. HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long term outcomes. Hepatol Int. 2016. doi:10.1007/s12072-016-9709-6. Lim TH, Gane E, Moyes C, Borman B, Cunningham C. HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long term outcomes. Hepatol Int. 2016. doi:10.​1007/​s12072-016-9709-6.
13.
Zurück zum Zitat Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, Chen DS, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011;141:517–525, 525.e511–e512 Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, Chen DS, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011;141:517–525, 525.e511–e512
14.
Zurück zum Zitat Yang HI, Tseng TC, Liu J, Lee MH, Liu CJ, Su TH, Batrla-Utermann R, et al. Incorporating serum level of hepatitis B surface antigen or omitting level of hepatitis B virus DNA does not affect calculation of risk for hepatocellular carcinoma in patients without cirrhosis. Clin Gastroenterol Hepatol 2016;14(461–468):e462 Yang HI, Tseng TC, Liu J, Lee MH, Liu CJ, Su TH, Batrla-Utermann R, et al. Incorporating serum level of hepatitis B surface antigen or omitting level of hepatitis B virus DNA does not affect calculation of risk for hepatocellular carcinoma in patients without cirrhosis. Clin Gastroenterol Hepatol 2016;14(461–468):e462
15.
Zurück zum Zitat Fung J, Seto WK, Wong DK, Lai CL, Yuen MF. Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study. Liver Int 2015;35:854–859 Fung J, Seto WK, Wong DK, Lai CL, Yuen MF. Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study. Liver Int 2015;35:854–859
16.
Zurück zum Zitat Liu J, Tseng TC, Yang HI, Lee MH, Batrla-Utermann R, Jen CL, Lu SN, et al. Predicting hepatitis B virus (HBV) surface antigen seroclearance in HBV e antigen-negative patients with chronic hepatitis B: external validation of a scoring system. J Infect Dis 2015;211:1566–1573 Liu J, Tseng TC, Yang HI, Lee MH, Batrla-Utermann R, Jen CL, Lu SN, et al. Predicting hepatitis B virus (HBV) surface antigen seroclearance in HBV e antigen-negative patients with chronic hepatitis B: external validation of a scoring system. J Infect Dis 2015;211:1566–1573
17.
Zurück zum Zitat Revill PA, Locarnini SA. New perspectives on the hepatitis B virus life cycle in the human liver. J Clin Invest 2016;126:833–836 Revill PA, Locarnini SA. New perspectives on the hepatitis B virus life cycle in the human liver. J Clin Invest 2016;126:833–836
18.
Zurück zum Zitat Zhang X, Lu W, Zheng Y, Wang W, Bai L, Chen L, Feng Y, et al. In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection. J Clin Invest 2016;126:1079–1092 Zhang X, Lu W, Zheng Y, Wang W, Bai L, Chen L, Feng Y, et al. In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection. J Clin Invest 2016;126:1079–1092
19.
Zurück zum Zitat Zhang Y, Mao R, Yan R, Cai D, Zhang Y, Zhu H, Kang Y, et al. Transcription of hepatitis B virus covalently closed circular DNA is regulated by cpg methylation during chronic infection. PLoS One 2014;9:e110442 Zhang Y, Mao R, Yan R, Cai D, Zhang Y, Zhu H, Kang Y, et al. Transcription of hepatitis B virus covalently closed circular DNA is regulated by cpg methylation during chronic infection. PLoS One 2014;9:e110442
20.
Zurück zum Zitat Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, Williams J, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010;51:1531–1537 Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, Williams J, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010;51:1531–1537
21.
Zurück zum Zitat Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, Lau K, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008;135:1192–1199 Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, Lau K, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008;135:1192–1199
Metadaten
Titel
HBsAg loss in chronic hepatitis B: pointers to the benefits of curative therapy
verfasst von
Geoffrey Dusheiko
Bo Wang
Ivana Carey
Publikationsdatum
31.05.2016
Verlag
Springer India
Erschienen in
Hepatology International / Ausgabe 5/2016
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-016-9738-1

Weitere Artikel der Ausgabe 5/2016

Hepatology International 5/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.